Nemaura Medical (NSDQ:NMRD) announced today that it commissioned the integration of data to its ProBeat app set for U.S. launch this year.
Data from third-party wearable devices can now be integrated into the ProBeat system, which is a wearable, non-invasive glucose monitor designed to gather big data centered around factors that affect blood glucose levels, according to a news release.
Loughborough, England-based Nemaura Medical said its predictive algorithms and artificial intelligence-based feedback and prompts, combined with the introduction of third-party data, can give users access to information that reveals the relationship between various activities and the factors affecting blood glucose levels.
Nemaura’s SugarBeat, which had its app launched last month, is designed for glucose monitoring on smart devices. In April, the company announced that the CGM is set to be repurposed for continuous temperature monitoring (CTM) to match with the SugarBeat patch, which is CE-marked in Europe and commercially available.
The company has also repurposed the device’s usage capabilities to aid in diagnosing fevers in potential cases of COVID-19 during the ongoing pandemic.